EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model

Ismail M Meraz iD, Mourad Majidi, Renduo Song, Feng Meng, Lihui Gao, Qi Wang, Jing Wang, Elizabeth J Shpall, Jack A Roth

eLife · 2025

DOI: 10.7554/elife.98258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Ismail M Meraz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Houston, United States. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins p21(ras), Genetic Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Genprex Inc, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Expression of NPRL2/TUSC4 , a tumor-suppressor gene, is reduced in many cancers including NSCLC. Restoration of NPRL2 induces DNA damage, apoptosis, and cell-cycle arrest. We investigated NPRL2 antitumor immune responses in aPD1 R / KRAS/STK11 mt NSCLC in humanized-mice. Humanized-mice were generated by transplanting fresh human cord blood-derived CD34 stem cells into sub-lethally irradiated NSG mice. Lung-metastases were developed from KRAS/STK11 mt /aPD1 R A549 cells and treated with NPRL2 w/wo pembrolizumab. NPRL2 -treatment reduced lung metastases significantly, whereas pembrolizumab was ineffective. Antitumor effect was greater in humanized than non-humanized-mice. NPRL2 + pembrolizumab was not synergistic in KRAS/STK11 mt /aPD1 R tumors but was synergistic in KRAS wt /aPD1 S H1299. NPRL2 also showed a significant antitumor effect on KRAS mt /aPD1 R LLC2 syngeneic-tumors. The antitumor effect was correlated with increased infiltration of human cytotoxic-T, HLA-DR + DC, CD11c + DC, and downregulation of myeloid and regulatory-T cells in TME. Antitumor effect was abolished upon in-vivo depletion of CD8-T, macrophages, and CD4-T cells whereas remained unaffected upon NK-cell depletion. A distinctive protein-expression profile was found after NPRL2 treatment. IFNγ, CD8b , and TBX21 associated with T-cell functions were significantly increased, whereas FOXP3, TGFB1/B2 , and IL-10RA were strongly inhibited by NPRL2 . A list of T-cell co-inhibitory molecules was also downregulated. Restoration of NPRL2 exhibited significantly slower tumor growth in humanized-mice, which was associated with increased presence of human cytotoxic-T, and DC and decreased percentage of Treg, MDSC, and TAM in TME. NPRL2 -stable cells showed a substantial increase in colony-formation inhibition and heightened sensitivity to carboplatin. Stable-expression of NPRL2 resulted in the downregulation of MAPK and AKT-mTOR signaling. Taken-together, NPRL2 gene-therapy induces antitumor activity on KRAS/STK11 mt /aPD1 R tumors through DC-mediated antigen-presentation and cytotoxic immune-cell activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungProto-Oncogene Proteins p21(ras)Genetic TherapyTumor Suppressor ProteinsAnimalsMiceHumansDisease Models, AnimalAntibodies, Monoclonal, HumanizedCell Line, TumorDrug Resistance, NeoplasmMutation

Stichwörter der Autor:innen

KRAS/STK11 mutationNSCLCanti-PD1 resistancecancer biologyhumanhumanized mouse modelmousenprl2 gene therapy

Substanzen

Proto-Oncogene Proteins p21(ras)Tumor Suppressor ProteinsKRAS protein, humanAntibodies, Monoclonal, Humanizedpembrolizumab

Autor:innen und Institutionen

  • Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Houston, United States.
  • Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Houston, United States.
  • Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Houston, United States.

ORCID-Profile: Ismail M Meraz

Förderung

  • NCI NIH HHS
  • Genprex Inc
  • National Cancer Institute

Zitieren

APA

Meraz, I. M., Majidi, M., Song, R., Meng, F., Gao, L., Wang, Q., Wang, J., Shpall, E. J., & Roth, J. A. (2025). NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model. eLife. https://doi.org/10.7554/elife.98258

Vancouver

Meraz IM, Majidi M, Song R, Meng F, Gao L, Wang Q, et al. NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model. eLife. 2025. doi:10.7554/elife.98258

BibTeX
@article{Meraz2025,
  author = {Meraz, Ismail M and Majidi, Mourad and Song, Renduo and Meng, Feng and Gao, Lihui and Wang, Qi and Wang, Jing and Shpall, Elizabeth J and Roth, Jack A},
  title = {NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model},
  journal = {eLife},
  year = {2025},
  doi = {10.7554/elife.98258}
}
Kostenlos starten →